quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:02:27·36d
SECFiling
IGC Pharma Inc. logo

SEC Form 10-KT filed by IGC Pharma Inc.

IGC· IGC Pharma Inc.
Health Care
Original source

Companies

  • IGC
    IGC Pharma Inc.
    Health Care

Related

  • NEWS1d
    IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
  • SEC3d
    IGC Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
  • NEWS3d
    IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia
  • NEWS9d
    IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
  • NEWS15d
    Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts
  • NEWS16d
    IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease
  • INSIDER17d
    SEC Form 4 filed by Prins Richard K
  • INSIDER17d
    SEC Form 4 filed by Mukunda Ram
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022